@entity2460 ( @entity2460 ) is a @entity361 of fibrous origin. The 2013 WHO classification of soft tissue tumors defines malignant forms as hypercellular, mitotically active (>4 mitosis/10 high-power fields), with cytological atypia, @entity5 necrosis, and/or infiltrative margins. With an IRB-approved protocol, we investigated @entity1 records and clinicopathologic data from our @entity242 Database to describe the clinical characteristics of both benign and malignant @entity2460 . All pathology specimens were reviewed by two pathologists. Descriptive statistics and univariate/multivariate survival analysis were performed. @entity1 records and Social Security Death Index were used to evaluate vital status. Of 82 @entity1 , 47 (57%) were @entity1 and 73 (89%) were Caucasian. Median age was 62 years (range, 20 to 89). Thirty-two (39%) @entity1 succumbed to the disease. Primary @entity5 site was lung/pleura in 28 (34%), abdomen/pelvis in 23 (28%), extremity in 13 (16%), and head/neck in 9 (11%) @entity1 . Pathology was described as benign in 42 (51%) and malignant in 40 (49%) @entity1 . Compared to benign @entity2460 , malignant histology is associated with larger @entity5 size, higher mitotic counts, @entity3 at diagnosis, and greater use of chemotherapy and radiation therapy. Gender, age, and @entity5 site were not significantly different between benign and malignant subtypes. By univariate analysis, only benign vs. malignant variant and complete resection positively impacted overall survival (P = 0.02 and P<0.0001, respectively). In the multivariable analysis of overall survival, receiving chemotherapy or not receiving surgery were two variables significantly associated with higher failure rate in overall survival: @entity1 with chemotherapy vs. no chemotherapy (P = 0.003, HR = 4.55, with 95% CI: 1.68-12.34) and @entity1 without surgery vs. with surgery (P = 0.005, HR = 25.49, with 95% CI: 2.62-247.57). Clear survival differences exist between benign and malignant @entity2460 . While surgery appears to be the best treatment option for benign and malignant @entity2460 , better systemic therapies are needed to improve outcomes of @entity1 with metastatic, malignant @entity2460 .

Clinical Characteristics and Outcomes for XXXX ( @entity2460 ): A Single Center Experience.

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient', 'Patient'] @entity242 :: ('MESH:D012509', 'Disease') :: ['Sarcoma'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastatic disease'] @entity361 :: ('MESH:C535700', 'Disease') :: ['mesenchymal neoplasm'] @entity2460 :: ('MESH:D054364', 'Disease') :: ['SFT', 'Solitary fibrous tumor']
@entity2460 :: (MESH:D054364,Disease) :: ['Solitary Fibrous Tumor']
